Circulating Biomarkers in the Management of Breast Cancer
- Authors: Ravindri Jayasinghe1, Umesh Jayarajah2, Sanjeewa Seneviratne3
-
View Affiliations Hide Affiliations1 Department of Surgery, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka 2 Department of Surgery, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka 3 Department of Surgery, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
- Source: Biomarkers in Medicine , pp 133-149
- Publication Date: August 2022
- Language: English
Circulating Biomarkers in the Management of Breast Cancer, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789815040463/chap7-1.gif
Circulating biomarkers have become a promising modality in the management of many cancers. Similarly, in breast cancer, circulatory biomarkers are useful, non-invasive methods in the diagnosis, prognostication, and evaluation of response to treatment. Invasive surgical biopsies can be potentially replaced by “liquid biopsy,” which involves analysing circulatory biomarkers that may reveal features of primary and metastatic disease. Therefore, providing an insight into the cancer biology can be utilised to monitor treatment response, treatment-induced adaptation and tumour and disease progression through non-invasive means. The objective of this review is to provide an overview of the current status of the circulating biomarkers highlighting their promising impact on the management of patients with breast cancer.
-
From This Site
/content/books/9789815040463.chap7dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
